Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
0.3931
Dollar change
0.0000
Percentage change
0.00
%
Index- P/E- EPS (ttm)-3.98 Insider Own11.25% Shs Outstand3.93M Perf Week-1.73%
Market Cap1.54M Forward P/E- EPS next Y-0.66 Insider Trans0.00% Shs Float3.49M Perf Month-14.56%
Income-7.79M PEG- EPS next Q-0.36 Inst Own7.79% Short Float2.04% Perf Quarter-33.37%
Sales0.00M P/S- EPS this Y48.31% Inst Trans-92.07% Short Ratio0.09 Perf Half Y-62.92%
Book/sh1.62 P/B0.24 EPS next Y52.17% ROA-104.46% Short Interest0.07M Perf Year-71.72%
Cash/sh1.89 P/C0.21 EPS next 5Y- ROE-125.96% 52W Range0.37 - 3.93 Perf YTD-35.56%
Dividend Est.- P/FCF- EPS past 5Y26.37% ROI-122.65% 52W High-90.00% Beta0.86
Dividend TTM- Quick Ratio4.91 Sales past 5Y0.00% Gross Margin- 52W Low6.21% ATR (14)0.04
Dividend Ex-Date- Current Ratio4.91 EPS Y/Y TTM72.66% Oper. Margin0.00% RSI (14)39.36 Volatility9.65% 7.78%
Employees8 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price1.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q74.96% Payout- Rel Volume0.00 Prev Close0.39
Sales Surprise- EPS Surprise42.31% Sales Q/Q- EarningsMar 22 BMO Avg Volume836.75K Price0.39
SMA20-5.20% SMA50-9.85% SMA200-55.96% Trades Volume0 Change0.00%
Mar-27-24 04:05PM
Mar-21-24 10:53PM
04:05PM
Feb-07-24 07:00AM
Feb-06-24 07:00AM
09:00AM Loading…
Feb-01-24 09:00AM
Jan-05-24 08:31AM
Jan-04-24 04:05PM
Dec-20-23 04:05PM
Nov-17-23 09:06AM
Nov-16-23 01:30PM
08:00AM
Nov-09-23 04:05PM
Oct-26-23 09:00AM
Aug-31-23 09:00AM
04:15PM Loading…
Aug-10-23 04:15PM
Jun-27-23 09:00AM
Jun-13-23 04:15PM
Jun-08-23 09:00AM
May-26-23 04:00PM
May-24-23 08:00AM
May-11-23 04:05PM
May-10-23 11:46AM
Apr-21-23 12:02PM
Apr-20-23 06:00AM
Mar-20-23 04:30PM
Mar-16-23 01:15PM
Feb-21-23 04:05PM
Dec-05-22 08:30AM
Nov-10-22 05:20PM
09:00AM Loading…
Sep-06-22 09:00AM
Aug-24-22 04:05PM
Aug-15-22 04:05PM
Jun-13-22 09:00AM
May-23-22 09:00AM
May-16-22 04:05PM
Apr-25-22 04:50PM
Apr-21-22 09:00AM
Mar-28-22 08:30AM
Mar-24-22 08:30AM
Feb-10-22 07:27AM
Feb-07-22 08:58AM
Jan-13-22 08:30AM
Jan-05-22 08:30AM
Nov-22-21 05:06AM
04:53AM
Nov-19-21 02:17PM
08:30AM
Nov-17-21 08:00AM
Nov-15-21 04:01PM
Nov-12-21 08:00AM
Nov-11-21 06:00AM
Oct-19-21 07:00AM
06:53AM
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.